Koomer Ajoy, Quinn Tim, Bamberger David, Herndon Betty L
University of Missouri-Kansas City School of Medicine, 2411 Holmes St, Kansas City, MO 64108, USA.
J Infect. 2006 May;52(5):320-8. doi: 10.1016/j.jinf.2005.07.017. Epub 2005 Sep 19.
To determine if differences in drug-related Staphylococcus aureus killing, associated in vivo with neutropenia, is neutrophil-related in vitro, and the mechanisms of this interaction.
To evaluate the influence of living neutrophils on drug-S. aureus interactions, cell wall enzymes, the PBPs, were isolated and their binding to five (beta lactam and other) antibiotics was evaluated following incubation (or not) with neutrophils. S. aureus killing by the test drugs was assayed in growth media of sterile filtered abscess fluid, either neutropenic infected or normal infected. At MBCs for the test isolate, each drug or saline control was incubated with S. aureus 10(6)and dilution-plated.
Neutrophil incubation with S. aureus eliminated the S. aureus PBP-2 band in all Western blots irrespective of the drug used to tag the PBPs. Time-kill of S. aureus grown in neutropenic or normal abscess fluid showed greater kill by all drugs in neutropenic abscess fluid (p=0.029 6h incubation). Killing difference between the media correlates with drug PBP-2 activity.
Drug activity against S. aureus in vitro is changed by neutrophil incubation. The neutrophil-induced loss of S. aureus PBP-2 drug binding suggests novel host-bacterial interaction that may impinge on drug treatment of S. aureus infections.
确定与中性粒细胞减少症在体内相关的药物性金黄色葡萄球菌杀伤差异在体外是否与中性粒细胞相关,以及这种相互作用的机制。
为评估活中性粒细胞对药物 - 金黄色葡萄球菌相互作用的影响,分离细胞壁酶即青霉素结合蛋白(PBPs),并在与中性粒细胞孵育(或未孵育)后评估其与五种(β - 内酰胺类和其他)抗生素的结合情况。在无菌过滤的脓肿液生长培养基中测定受试药物对金黄色葡萄球菌的杀伤作用,脓肿液分为中性粒细胞减少感染组和正常感染组。在受试菌株的最低杀菌浓度(MBC)下,将每种药物或生理盐水对照与10⁶的金黄色葡萄球菌孵育并进行稀释平板培养。
在所有蛋白质免疫印迹中,无论用于标记PBPs的药物如何,金黄色葡萄球菌与中性粒细胞孵育均消除了金黄色葡萄球菌PBP - 2条带。在中性粒细胞减少或正常脓肿液中生长的金黄色葡萄球菌的时间杀菌曲线显示,在中性粒细胞减少的脓肿液中所有药物的杀伤作用更强(孵育6小时,p = 0.029)。培养基之间的杀伤差异与药物PBP - 2活性相关。
中性粒细胞孵育会改变体外药物对金黄色葡萄球菌的活性。中性粒细胞诱导的金黄色葡萄球菌PBP - 2药物结合丧失提示了一种可能影响金黄色葡萄球菌感染药物治疗的新型宿主 - 细菌相互作用。